HRP20140015T1 - Antitumorski spojevi - Google Patents

Antitumorski spojevi Download PDF

Info

Publication number
HRP20140015T1
HRP20140015T1 HRP20140015AT HRP20140015T HRP20140015T1 HR P20140015 T1 HRP20140015 T1 HR P20140015T1 HR P20140015A T HRP20140015A T HR P20140015AT HR P20140015 T HRP20140015 T HR P20140015T HR P20140015 T1 HRP20140015 T1 HR P20140015T1
Authority
HR
Croatia
Prior art keywords
substituted
unsubstituted
hydrogen
compound according
image
Prior art date
Application number
HRP20140015AT
Other languages
English (en)
Croatian (hr)
Inventor
Alberto RODRÍGUEZ VICENTE
María GARRANZO GARCÍA-IBARROLA
Carmen MURCIA PÉREZ
Francisco SÁNCHEZ SANCHO
María del Carmen CUEVAS MARCHANTE
Cristina Mateo Urbano
Isabel Digón Juárez
Original Assignee
Pharma Mar, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar, S.A. filed Critical Pharma Mar, S.A.
Publication of HRP20140015T1 publication Critical patent/HRP20140015T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
HRP20140015AT 2007-12-20 2008-12-19 Antitumorski spojevi HRP20140015T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07123882 2007-12-20
PCT/EP2008/068049 WO2009080761A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Publications (1)

Publication Number Publication Date
HRP20140015T1 true HRP20140015T1 (hr) 2014-02-14

Family

ID=40580474

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20140015AT HRP20140015T1 (hr) 2007-12-20 2008-12-19 Antitumorski spojevi
HRP20120464AT HRP20120464T1 (hr) 2007-12-20 2008-12-19 Antitumorski spojevi

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20120464AT HRP20120464T1 (hr) 2007-12-20 2008-12-19 Antitumorski spojevi

Country Status (26)

Country Link
US (4) US8710264B2 (enExample)
EP (3) EP2231633B1 (enExample)
JP (3) JP5529038B2 (enExample)
KR (3) KR101639772B1 (enExample)
CN (4) CN102190643B (enExample)
AT (1) ATE549313T1 (enExample)
AU (2) AU2008341671B2 (enExample)
BR (2) BRPI0821116B8 (enExample)
CA (2) CA2715203C (enExample)
CY (1) CY1117245T1 (enExample)
DK (2) DK2231590T3 (enExample)
ES (3) ES2384420T3 (enExample)
HR (2) HRP20140015T1 (enExample)
IL (3) IL206396A (enExample)
MX (2) MX2010006795A (enExample)
MY (3) MY148651A (enExample)
NZ (3) NZ597526A (enExample)
PL (2) PL2231590T3 (enExample)
PT (2) PT2231590E (enExample)
RS (2) RS53140B (enExample)
RU (3) RU2493147C2 (enExample)
SG (2) SG170778A1 (enExample)
SI (2) SI2231590T1 (enExample)
UA (3) UA106967C2 (enExample)
WO (2) WO2009080769A1 (enExample)
ZA (3) ZA201004017B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi
WO2013103155A1 (en) * 2012-01-05 2013-07-11 Kao Corporation Agent for reduction of sensory irritation
MA38588B1 (fr) 2013-04-16 2018-04-30 Idorsia Pharmaceuticals Ltd Dérivés bi-aromatiques antibactériens
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
US6528510B1 (en) 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
AU2000241948A1 (en) * 2000-04-04 2001-10-15 Novartis Ag Method for treating cells resistant to antineoplastic agents
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
AU2004263287B2 (en) * 2003-07-25 2009-02-12 Novartis Ag Substituted lactams and their use as anti-cancer agents
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
EP2404912A3 (en) 2006-06-16 2012-07-25 Pharma Mar S.A. Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi

Also Published As

Publication number Publication date
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
BRPI0821114B1 (pt) 2021-09-08
JP2014133752A (ja) 2014-07-24
EP2231590B1 (en) 2012-03-14
HK1147990A1 (en) 2011-08-26
MY155342A (en) 2015-10-15
BRPI0821114B8 (pt) 2021-11-09
RU2493147C2 (ru) 2013-09-20
IL206397A (en) 2014-01-30
JP5529038B2 (ja) 2014-06-25
JP5860088B2 (ja) 2016-02-16
CN101903367A (zh) 2010-12-01
IL206396A (en) 2014-05-28
CN102174058A (zh) 2011-09-07
US9187445B2 (en) 2015-11-17
HK1180678A1 (en) 2013-10-25
IL206396A0 (en) 2010-12-30
US20120041063A2 (en) 2012-02-16
EP2231633B1 (en) 2013-10-30
JP5727228B2 (ja) 2015-06-03
IL206397A0 (en) 2010-12-30
MX2010006796A (es) 2010-10-26
UA106967C2 (uk) 2014-11-10
MY164533A (en) 2017-12-29
RU2013112003A (ru) 2014-08-20
DK2231590T3 (da) 2012-07-09
US20150344454A1 (en) 2015-12-03
ES2442140T3 (es) 2014-02-25
JP2011506575A (ja) 2011-03-03
CN102190643A (zh) 2011-09-21
PL2231633T3 (pl) 2014-03-31
SI2231590T1 (sl) 2012-10-30
RU2528393C9 (ru) 2015-01-10
EP2231633A1 (en) 2010-09-29
EP2597091A1 (en) 2013-05-29
IL229594A (en) 2016-02-29
AU2008341670B2 (en) 2012-04-19
PT2231590E (pt) 2012-06-25
UA104281C2 (ru) 2014-01-27
RU2528393C1 (ru) 2014-09-20
ZA201106371B (en) 2013-05-29
CN101903367B (zh) 2015-08-05
BRPI0821116B1 (pt) 2020-02-18
JP2011506578A (ja) 2011-03-03
CN101903337A (zh) 2010-12-01
HK1147998A1 (en) 2011-08-26
RS52343B (sr) 2012-12-31
SI2231633T1 (sl) 2014-02-28
ES2384420T3 (es) 2012-07-04
AU2008341671B2 (en) 2012-07-26
KR20150076265A (ko) 2015-07-06
SG170779A1 (en) 2011-05-30
HRP20120464T1 (hr) 2012-07-31
ZA201004018B (en) 2011-12-28
US9827257B2 (en) 2017-11-28
CA2710087A1 (en) 2009-07-02
BRPI0821116A2 (pt) 2015-08-11
MX2010006795A (es) 2010-10-26
AU2008341670A1 (en) 2009-07-02
CN101903337B (zh) 2013-12-18
KR101541436B1 (ko) 2015-08-03
IL229594A0 (en) 2014-01-30
US8710264B2 (en) 2014-04-29
RS53140B (sr) 2014-06-30
CN102190643B (zh) 2015-02-25
RU2010130180A (ru) 2012-01-27
KR101579553B1 (ko) 2015-12-22
RU2489429C2 (ru) 2013-08-10
WO2009080761A1 (en) 2009-07-02
BRPI0821116B8 (pt) 2021-05-25
SG170778A1 (en) 2011-05-30
CA2710087C (en) 2015-06-02
US20150342972A1 (en) 2015-12-03
KR101639772B1 (ko) 2016-07-15
MY148651A (en) 2013-05-15
UA119963C2 (uk) 2019-09-10
US9750759B2 (en) 2017-09-05
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
EP2231590B9 (en) 2012-08-15
DK2231633T3 (da) 2014-01-20
CA2715203C (en) 2015-09-08
BRPI0821114A2 (pt) 2015-06-16
EP2597091B1 (en) 2016-04-20
AU2008341671A1 (en) 2009-07-02
ATE549313T1 (de) 2012-03-15
KR20100125226A (ko) 2010-11-30
ES2578606T3 (es) 2016-07-28
EP2231590A1 (en) 2010-09-29
PL2231590T3 (pl) 2012-09-28
US20110034549A1 (en) 2011-02-10
ZA201004017B (en) 2011-12-28
RU2010130253A (ru) 2012-01-27
NZ586013A (en) 2012-02-24
KR20100100979A (ko) 2010-09-15
NZ597526A (en) 2012-06-29
CY1117245T1 (el) 2017-04-05
CA2715203A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
HRP20110845T1 (hr) Antitumorski dihidropiran-2-onski spojevi
EP4159717A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator
RU2019118460A (ru) Новые соединения замещенного n-(3-фторпропил)пирролидина, способы их получения и их терапевтическое применение
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
BR112014019478A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença.
HRP20120464T1 (hr) Antitumorski spojevi
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
HRP20151258T1 (hr) Derivat aminopirazola
HRP20211043T1 (hr) Derivati 6,7-dihidro-5h-benzo[7]anulena kao modulatori estrogenskih receptora
NO20064309L (no) Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer
PE20250759A1 (es) Conjugado de anticuerpo bispecifico-farmaco de camptotecina y uso farmaceutico de este
AR106942A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
MY201700A (en) Methods of making incretin analogs
HRP20120785T1 (hr) Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze
ZA200503841B (en) Combination administration of an indolinone with achemotherapeutic agent for cell proliferation dis orders
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
CA2797533A1 (en) Compounds that modulate intracellular calcium
EA201290520A1 (ru) Производные дифенилпиразолопиридинов, их получение и применение в качестве модуляторов нуклеарного рецептора not
JP2017510570A5 (enExample)
MA38935B1 (fr) Dérivés de diazacarbazole à titre de ligands tau-pet
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
PE20081368A1 (es) Derivados de azabiciclo[4.1.0]heptano como inhibidores de la recaptacion de serotonina, dopamina y norepinefrina
RU2015135722A (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
WO2015200837A1 (en) Abiraterone derivatives and non-covalent complexes with albumin
AR116022A1 (es) Compuestos heteroaromáticos como inhibidores de vanina